Months af­ter a ma­jor re­brand­ing around CAR-NKT cells, Ku­ur Ther­a­peu­tics is of­fer­ing a peek at ear­ly re­sults

Sev­er­al months af­ter a name change and ma­jor re­struc­tur­ing, Ku­ur Ther­a­peu­tics has of­fered an ear­ly glimpse at re­sults from a small num­ber of pa­tients treat­ed with their CAR-NKT cell ther­a­pies de­vel­oped with the Bay­lor Col­lege of Med­i­cine.

Out of 10 evalu­able neu­rob­las­toma pa­tients dosed with Ku­ur’s lead can­di­date, an au­tol­o­gous GD2-tar­get­ing CAR-NKT ther­a­py, re­searchers not­ed one com­plete re­sponse, one par­tial re­sponse, and three pa­tients with sta­ble dis­ease, ac­cord­ing to the Hous­ton-based biotech.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER